Hainan Poly Pharm. Co., Ltd

SZSE:300630 Stock Report

Market Cap: CN¥5.1b

Hainan Poly Pharm Past Earnings Performance

Past criteria checks 0/6

Hainan Poly Pharm's earnings have been declining at an average annual rate of -18.2%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 9% per year.

Key information

-18.2%

Earnings growth rate

-19.3%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate9.0%
Return on equity-2.4%
Net Margin-5.3%
Next Earnings Update28 Oct 2024

Recent past performance updates

Recent updates

Hainan Poly Pharm. Co., Ltd (SZSE:300630) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Aug 16
Hainan Poly Pharm. Co., Ltd (SZSE:300630) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

It's Down 27% But Hainan Poly Pharm. Co., Ltd (SZSE:300630) Could Be Riskier Than It Looks

Apr 21
It's Down 27% But Hainan Poly Pharm. Co., Ltd (SZSE:300630) Could Be Riskier Than It Looks

A Piece Of The Puzzle Missing From Hainan Poly Pharm. Co., Ltd's (SZSE:300630) 27% Share Price Climb

Mar 06
A Piece Of The Puzzle Missing From Hainan Poly Pharm. Co., Ltd's (SZSE:300630) 27% Share Price Climb

Revenue & Expenses Breakdown

How Hainan Poly Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300630 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241,272-68707247
31 Mar 241,39686671261
31 Dec 231,30486644268
30 Sep 231,23771499235
30 Jun 231,294104515262
31 Mar 231,466200477268
31 Dec 221,619295483263
30 Sep 221,743482338283
30 Jun 221,681479331252
31 Mar 221,603457327236
01 Jan 221,509417315229
30 Sep 211,543513317230
30 Jun 211,410474299224
31 Mar 211,291449264217
31 Dec 201,189407250191
30 Sep 201,124380280237
30 Jun 201,000340258188
31 Mar 20964311265186
31 Dec 19950301266184
30 Sep 19830266240168
30 Jun 19725231196158
31 Mar 19687220197145
31 Dec 18624181187138
30 Sep 18528159151119
30 Jun 18445137117116
31 Mar 1837111910279
31 Dec 173259810063
30 Sep 172988911527
30 Jun 17275781290
31 Mar 17260721240
31 Dec 16248701150
30 Jun 16214561020
31 Mar 1619350900
31 Dec 1520351970
31 Dec 1416537810
31 Dec 1313225650

Quality Earnings: 300630 is currently unprofitable.

Growing Profit Margin: 300630 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300630 is unprofitable, and losses have increased over the past 5 years at a rate of 18.2% per year.

Accelerating Growth: Unable to compare 300630's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 300630 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.6%).


Return on Equity

High ROE: 300630 has a negative Return on Equity (-2.38%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies